Transactions in connection with share buy-back program
04 mars 2024 04h29 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 4, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
01 mars 2024 18h04 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 02, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
29 févr. 2024 10h48 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 29, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
27 févr. 2024 15h42 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
27 févr. 2024 15h40 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The...
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
26 févr. 2024 19h45 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating...
Transactions in connection with share buy-back program
26 févr. 2024 05h21 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
23 févr. 2024 17h50 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
23 févr. 2024 17h35 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and...
Transactions in connection with share buy-back program
19 févr. 2024 04h40 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 19, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments...